Form 8-K Sagent Pharmaceuticals, For: Nov 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Sagent Pharmaceuticals (SGNT) Tops Q3 EPS by 1c
November 3, 2015 8:47 AM ESTSagent Pharmaceuticals (NASDAQ: SGNT) reported Q3 EPS of ($0.05), $0.01 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $75.2 million versus the consensus estimate of $73.84 million.
Sagent Pharmaceuticals reaffirmed FY2015 guidance.
For earnings history and earnings-related data on Sagent Pharmaceuticals (SGNT) click here.
... More